Skip to main content

Advertisement

SpringerLink
Log in

Cancer in inflammatory bowel disease

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Abstract

  • Colorectal cancer (CRC) is a complication in both patients with longstanding ulcerative colitis and those with Crohn’s disease. As with sporadic CRC, surgical therapy (with adjuvant chemotherapy in advanced disease) is the only effective treatment.

  • Identifying risk factors for CRC in inflammatory bowel disease (IBD) should allow patients to receive appropriate medical, endoscopic, and surgical care to minimize CRC morbidity and mortality.

  • Total proctocolectomy remains the most effective form of cancer prophylaxis in IBD patients, but because of the impact of this approach and the low absolute risk of cancer, clinicians seldom recommend it.

  • Colonoscopic surveillance with systematic biopsies is used to detect mucosal dysplasia and thus identify those patients at greatest risk for developing CRC. Patients with dysplasia other than that in readily excised polyps should be referred for surgery. Although fraught with limitations, surveillance is the best method currently available for reducing CRC mortality and morbidity short of prophylactic colectomy. It will have to remain the standard of practice until better diagnostic tests are available. Surveillance should be offered and performed in the same manner for patients with Crohn’s disease and ulcerative colitis.

  • Chemoprevention may prove effective in the future, but currently used agents have only a modest benefit, if any.

  • Adenocarcinoma of the small intestine occurs at an increased rate in patients with Crohn’s disease of the bowel with longstanding small bowel involvement, but there are no current methods of early detection. Treatment is based on disease identified from evaluation of symptoms or incidental finding.

  • Some extraintestinal cancers have been noted to occur at increased rates in series from referral centers but not in population-based studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Crohn BB, Rosenberg H: The sigmoidoscopic picture of chronic ulcerative colitis. Am J Med Sci 1925, 170:220–228.

    Article  Google Scholar 

  2. Ekbom A, Helmick C, Zack M, Adami HO: Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990, 323:1228–1233. Although an older reference, this work remains the seminal epidemiologic study of colorectal cancer complicating ulcerative colitis.

    Article  PubMed  CAS  Google Scholar 

  3. Katzka I, Brody RS, Morris E, Katz S: Assessment of colorectal cancer risk in patients with ulcerative colitis: experience from a private practice. Gastroenterology 1983, 85:22–29.

    PubMed  CAS  Google Scholar 

  4. Greenstein AJ, Sachar DB, Pucillo A, et al.: Cancer in universal and left-sided ulcerative colitis: factors determining risk. Gastroenterology 1979, 77:290–294.

    PubMed  CAS  Google Scholar 

  5. Eaden JA, Abrams KR, Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001, 48:526–535.

    Article  PubMed  CAS  Google Scholar 

  6. Wong NA, Harrison DJ: Colorectal neoplasia in ulcerative colitis-recent advances. Histopathology 2001, 39:221–234. An excellent review, particularly of the molecular basis of cancer complicating colitis.

    Article  PubMed  CAS  Google Scholar 

  7. Brentnall TA, Haggitt RC, Rabinovitch PS, et al.: Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1996, 110:331–338.

    Article  PubMed  CAS  Google Scholar 

  8. Broome U, Lofberg R, Veress B, Eriksson LS: Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995, 22:1404–1408.

    PubMed  CAS  Google Scholar 

  9. Broome U, Lindberg G, Lofberg R: Primary sclerosing cholangitis in ulcerative colitis—a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology 1992, 102:1877–1880.

    PubMed  CAS  Google Scholar 

  10. D’Haens GR, Lashner BA, Hanauer SB: Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol 1993, 88:1174–1178.

    PubMed  CAS  Google Scholar 

  11. Marchesa P, Lashner BA, Lavery IC, et al.: The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1997, 92:1285–1288.

    PubMed  CAS  Google Scholar 

  12. Loftus EV Jr, Aguilar HI, Sandborn WJ, et al.: Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology 1998, 27:685–690.

    Article  PubMed  Google Scholar 

  13. Nuako KW, Ahlquist DA, Mahoney DW, et al.: Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology 1998, 115:1079–1083.

    Article  PubMed  CAS  Google Scholar 

  14. Askling J, Dickman PW, Karlen P, et al.: Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001, 120:1356–1362.

    Article  PubMed  CAS  Google Scholar 

  15. Reiser JR, Waye JD, Janowitz HD, Harpaz N, et al.: Adenocarcinoma in strictures of ulcerative colitis without antecedent dysplasia by colonoscopy. Am J Gastroenterol 1994, 89:119–122.

    PubMed  CAS  Google Scholar 

  16. Goulston SJ, McGovern VJ: Nature of strictures in chronic ulcerative colitis. Gut 1969, 10:952.

    PubMed  CAS  Google Scholar 

  17. Gillen CD, Walmsley RS, Prior P, et al.: Ulcerative colitis and Crohn’s disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 1994, 35:1590–1592. The comparison that ultimately was made put Crohn’s disease and ulcerative colitis on equal footing for considering risk of adenocarcinoma of the colon.

    PubMed  CAS  Google Scholar 

  18. Sachar DB: Cancer in Crohn’s disease: dispelling the myths. Gut 1994, 35:1507–1508. This editorial, which accompanied the original report by Gillen et al. [17], is a “must read.” It both rationally and concisely explains why we must treat patients with Crohn’s disease as we treat those with ulcerative colitis when considering risk for developing CRC.

    PubMed  CAS  Google Scholar 

  19. Choi PM, Zelig MP: Similarity of colorectal cancer in Crohn’s disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 1994, 35:950–954.

    PubMed  CAS  Google Scholar 

  20. Ekbom A, Helmick C, Zack M, et al.: Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet 1990, 336:357–359.

    Article  PubMed  CAS  Google Scholar 

  21. Munkholm P, Langholz E, Davidsen M, et al.: Intestinal cancer risk and mortality in patients with Crohn’s disease. Gastroenterology 1993, 105:1716–1723.

    PubMed  CAS  Google Scholar 

  22. Gyde SN, Prior P, Macartney JC, et al.: Malignancy in Crohn’s disease. Gut 1980, 21:1024–1029.

    PubMed  CAS  Google Scholar 

  23. Persson PG, Karlen P, Bernell O, et al.: Crohn’s disease and cancer: a population-based cohort study. Gastroenterology 1994, 107:1675–1679.

    PubMed  CAS  Google Scholar 

  24. Bernstein CN, Blanchard JF, Kliewer E, Wajda A: Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001, 91:854–862. A well-designed population-based analysis of cancer risk in both patients with Crohn’s disease and those with ulcerative colitis. The study was large enough in size to make meaningful inferences about cancer risk in a North American IBD population.

    Article  PubMed  CAS  Google Scholar 

  25. Ekbom A, Helmick C, Zack M, et al.: Extracolonic malignancies in inflammatory bowel disease. Cancer 1991, 67:2015–2019.

    Article  PubMed  CAS  Google Scholar 

  26. Greenstein AJ, Gennuso R, Sachar DB, et al.: Extraintestinal cancers in inflammatory bowel disease. Cancer 1985, 56:2914–2921.

    Article  PubMed  CAS  Google Scholar 

  27. Kornbluth A, Sachar DB: Ulcerative colitis practice guidelines in adults. American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol 1997, 92:204–211.

    PubMed  CAS  Google Scholar 

  28. Levin B, Lennard-Jones J, Riddell RH, et al.: Surveillance of patients with chronic ulcerative colitis. WHO Collaborating Centre for the Prevention of Colorectal Cancer. Bull World Health Organ 1991, 69:121–126.

    PubMed  CAS  Google Scholar 

  29. Karlen P, Kornfeld D, Brostrom O, et al.: Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut 1998, 42:711–714. The closest we may ever have to a “trial” of the effectiveness of surveillance colonoscopy. Unfortunately, the results were not statistically significant, although the point estimates of effect were clinically impressive.

    Article  PubMed  CAS  Google Scholar 

  30. Choi PM, Nugent FW, Schoetz DJ Jr, et al.: Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 1993, 105:418–424.

    PubMed  CAS  Google Scholar 

  31. Delco F, Sonnenberg A: A decision analysis of surveillance for colorectal cancer in ulcerative colitis. Gut 2000, 46:500–506.

    Article  PubMed  CAS  Google Scholar 

  32. Gage TP: Managing the cancer risk in chronic ulcerative colitis. A decision-analytic approach. J Clin Gastroenterol 1986, 8:50–57.

    Article  PubMed  CAS  Google Scholar 

  33. Provenzale D, Kowdley KV, Arora S, Wong JB: Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis. Gastroenterology 1995, 109:1188–1196.

    Article  PubMed  CAS  Google Scholar 

  34. Bernstein CN, Shanahan F, Weinstein WM: Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994, 343:71–74. Summarizes the results of prospective trials of surveillance, and, among other findings, demonstrated a high rate of synchronous cancer in patients with early surgery for low-grade dysplasia, albeit in small numbers.

    Article  PubMed  CAS  Google Scholar 

  35. Connell WR, Lennard-Jones JE, Williams CB, et al.: Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994, 107:934–944.

    PubMed  CAS  Google Scholar 

  36. Ullman TA, Loftus EV, Tremaine WJ, Sandborn WJ: Fate of Low-grade dysplasia in ulcerative colitis [abstract]. Gastroenterology 1999, 116:A522.

    Google Scholar 

  37. Morson BC, Pang LS: Rectal biopsy as an aid to cancer control in ulcerative colitis. Gut 1967, 8:423–434.

    PubMed  CAS  Google Scholar 

  38. Ransohoff DF, Riddell RH, Levin B: Ulcerative colitis and colonic cancer. Problems in assessing the diagnostic usefulness of mucosal dysplasia. Dis Colon Rectum 1985, 28:383–388.

    Article  PubMed  CAS  Google Scholar 

  39. Taylor BA, Pemberton JH, Carpenter HA, et al.: Dysplasia in chronic ulcerative colitis: implications for colonoscopic surveillance. Dis Colon Rectum 1992, 35:950–956.

    Article  PubMed  CAS  Google Scholar 

  40. Rubin CE, Haggitt RC, Burmer GC, et al.: DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992, 103:1611–1620.

    PubMed  CAS  Google Scholar 

  41. Eaden JA, Ward BA, Mayberry JF: How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. Gastrointest Endosc 2000, 51:123–128.

    Article  PubMed  CAS  Google Scholar 

  42. Ullman T: Assessment of biopsy practices in colonoscopic surveillance in ulcerative colitis. Gastroenterology 2001, 120:A446.

    Article  Google Scholar 

  43. Riddell RH, Goldman H, Ransohoff DF, et al.: Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983, 14:931–968.

    Article  PubMed  CAS  Google Scholar 

  44. Melville DM, Jass JR, Morson BC, et al.: Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome. Hum Pathol 1989, 20:1008–1014.

    Article  PubMed  CAS  Google Scholar 

  45. Lynch DA, Lobo AJ, Sobala GM, et al.: Failure of colonoscopic surveillance in ulcerative colitis. Gut 1993, 34:1075–1080.

    PubMed  CAS  Google Scholar 

  46. Lashner BA, Kane SV, Hanauer SB: Colon cancer surveillance in chronic ulcerative colitis: historical cohort study. Am J Gastroenterol 1990, 85:1083–1087.

    PubMed  CAS  Google Scholar 

  47. Friedman S, Rubin PH, Bodian C, et al.: Screening and surveillance colonoscopy in chronic Crohn’s colitis. Gastroenterology 2001, 120:820–826.

    Article  PubMed  CAS  Google Scholar 

  48. Bansal P, Sonnenberg A: Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 1996, 91:44–48.

    PubMed  CAS  Google Scholar 

  49. Eaden J, Abrams K, Ekbom A, et al.: Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000, 14:145–153.

    Article  PubMed  CAS  Google Scholar 

  50. Moody GA, Jayanthi V, Probert CS, et al.: Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996, 8:1179–1183.

    PubMed  CAS  Google Scholar 

  51. Pinczowski D, Ekbom A, Baron J, et al.: Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994, 107:117–120.

    PubMed  CAS  Google Scholar 

  52. Tung BY, Emond MJ, Haggitt RC, et al.: Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001, 134:89–95. Although not yet duplicated in terms of its findings of a risk reduction in patients with primary sclerosing cholangitis, this study is in many ways a model of a chemoprevention trial.

    PubMed  CAS  Google Scholar 

  53. Lashner BA, Heidenreich PA, Su GL, et al.: Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology 1989, 97:255–259.

    PubMed  CAS  Google Scholar 

  54. Lashner BA, Provencher KS, Seidner DL, et al.: The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997, 112:29–32.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dr. Henry D. Janowitz Division of Gastroenterology, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1069, 10029, New York, NY, USA

    Thomas A. Ullman MD

Authors
  1. Thomas A. Ullman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ullman, T.A. Cancer in inflammatory bowel disease. Curr Treat Options Gastro 5, 163–171 (2002). https://doi.org/10.1007/s11938-002-0038-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-002-0038-6

Keywords

Search

Navigation